Merck & Co., Inc. (MRK) operating KPIs
MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30242% above fair value
$146.33+5.40 (+3.83%)
Close on Oct 29, 2026Market cap $361.02BP/E 117.1Yield 2.24%
Merck winrevair (sotatercept — PAH activin signaling inhibitor, launched Q2 2024) — U.S. sales ($M) ($M)
Form 10-Q / 10-K Segment & Product Sales Footnote & Form 8-K Table 3 / 3a / 3b
Latest, Q2 2026
522
Period ended Jun 30, 2026
Change on a year earlier
+61.6%
323 in Q2 2025
History
13 quarters
Since Q2 2023
Sources
9
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Winrevair (sotatercept — PAH activin signaling inhibitor, launched Q2 2024) — U.S. sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 522 | +61.6% | Form 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗ |
| Q1 2026 | Mar 31, 2026 | 477 | +78.0% | Form 10-Q (filed 2026-05-04) ↗ |
| Q4 2025 | Dec 31, 2025 | 432 | +125.0% | Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗ |
| Q3 2025 | Sep 30, 2025 | 335 | +127.9% | Form 8-K (tm2529620d1_ex99-1.htm, filed 2025-10-30) ↗ |
| Q2 2025 | Jun 30, 2025 | 323 | +361.4% | Form 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗ |
| Q1 2025 | Mar 31, 2025 | 268 | – | Form 10-Q (filed 2026-05-04) ↗ |
| Q4 2024 | Dec 31, 2024 | 192 | – | Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗ |
| Q3 2024 | Sep 30, 2024 | 147 | – | Form 8-K (tm2529620d1_ex99-1.htm, filed 2025-10-30) ↗ |
| Q2 2024 | Jun 30, 2024 | 70 | – | Form 10-Q (filed 2025-08-05) ↗ |
| Q1 2024 | Mar 31, 2024 | 0 | – | Form 10-Q (filed 2025-05-02) ↗ |
| Q4 2023 | Dec 31, 2023 | 0 | – | Form 10-K (filed 2026-02-24) ↗ |
| Q3 2023 | Sep 30, 2023 | 0 | – | Form 10-Q (filed 2024-11-06) ↗ |
| Q2 2023 | Jun 30, 2023 | 0 | – | Form 10-Q (filed 2024-08-05) ↗ |
Cite this data
StockData. (2026). Merck Winrevair (sotatercept — PAH activin signaling inhibitor, launched Q2 2024) — U.S. sales ($M) ($M), quarterly Q2 2023–Q2 2026 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev_winrevair_us
See every metric in the Merck KPI table. Data updated Oct 26, 2026.